

## **Iron Sucrose Recurrent Treatment**

Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First		,	DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X)				

This form is intended for submitting treatment requests to hospital Day Medicine departments.

Note: As part of a pilot project, only **Red Deer Regional Hospital Centre Day Medicine** is currently set up to receive referrals through this process.

Referrals may be submitted by **physicians with admitting privileges at Red Deer Hospital**, with or without Connect Care access. All referring prescribers must include current telephone contact information and remain available to Day Medicine staff during regular business hours

, , , , , , , , , , , , , , , , , , ,	<i></i>					
Treatment Requirements						
Type of Treatment		□ New	☐ Renewa	al		
Consent for Treatment - Required	☐ Attached	Past Medical History	y - Required	☐ Attached		
Current Medications - Required	☐ Attached					
Relevant Blood Work  Blood work must be within 1 month of referen	☐ Attached al except Type a	and Screen which must	be within 96 hours			
Allergies			□ No Kr	nown Allergies		
Goals of Care Designation						
□ R1 □ R2 □ R3	□ M1	□ M2	□ C1	□ C2		
Confirm Indication for Treatment						
Low ferritin, and at least 1 of the following	ng: (choose at	least one)	Low ferritin			
<ul> <li>□ symptomatic (dyspnea, chest pain, lightheaded, syncope, ongoing bleeding)</li> <li>□ asymptomatic but with Hgb less than 80g/l</li> <li>□ failure to respond to adequate trial of oral iron (specify types and duration of therapy trailed)</li> <li>□ known to have malabsorption</li> </ul>			<ul> <li>15 yrs. or greater:</li> <li>Male ferritin less than 30 mcg</li> <li>Females less than 20mcg/l.</li> <li>Under 15 yrs.:</li> <li>ferritin less than 15 mcg/l</li> </ul>			
Appointment Request						
☑ Infusion Appointment Request:	□ Every	weeks for	treatments			
Labs						
Referring provider is responsible for ordering and managing all relevant Lab tests (such as CBC with Differential, Reticulocyte Count, Ferritin, Iron/TIBC, Phosphate)						
Patient Care Orders						
<ul> <li>✓ Nursing Communication Monitor for Fishbane reaction: Transient flushing, back and chest tightness/pain with joint pains</li> <li>✓ Stop infusion immediately, assess patient symptoms and vital signs</li> <li>✓ Observe patient for the next 5-10 minutes, do not treat if only mild symptoms</li> <li>✓ If symptoms subside restart infusion at half the starting rate; if symptoms worsen and/or patient becomes hypotensive then follow Anaphylaxis protocol</li> <li>✓ Notify attending physician for any concerns</li> </ul>						

22214 (Rev2025-10) Page 1 of 3



### Iron Sucrose Recurrent Treatment

Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X)				

### **Patient Care Orders continued**

### ✓ Nursing Communication

Anaphylaxis Protocol for Iron Infusions

- Stop infusion. Switch IV iron tubing to IV NaCl 0.9% and administer NaCl 0.9% as fast as possible, if clinically appropriate
- Administer IM EPINEPHrine 0.3 mg to mid anterior lateral thigh. Repeat dose PRN every 5 minutes to a maximum of 3 doses.
- Notify attending physician Anaphylaxis Protocol for Iron Infusions

# ✓ Nursing Communication

■ Monitor for hypersensitivity reactions, including BP, at baseline, then every 15 to 30 minutes during the infusion, and for 30 minutes after the end of the infusion, or until clinically stable.

# ✓ Nursing Communication

- Monitor IV site for symptoms of extravasation.
- If extravasation occurs: Stop the IV, aspirate as much drug as possible and remove the needle/catheter if peripheral.
- Apply cold compresses to affected area and elevate limb. Do not massage the area.

### ✓ Nursing Communication

- Observe for 30 minutes after infusion for delayed reaction: backache, muscle pains, chills, dizziness, fever, headache, nausea and/or vomiting.
- Educate Patient that reactions may occur 24 to 48 hours after onset of infusion and usually subside in 3 to 7 days

# Pre-Medications ☐ methlyPREDNISolone 40mg IV, 30 minutes prior Infusion ☑ Vital Signs – per protocol ☐ Iron Sucrose 300 mg IV once, Every \_\_\_\_\_ weeks ☐ Iron Sucrose 200 mg IV once, Every \_\_\_\_ weeks Emergency Medications ☑ Epinephrine 1 mg/mL for 0.3mg intramuscular, Once, as needed for anaphylaxis. Administer to mid-

☑ Epinephrine 1 mg/mL for 0.3mg intramuscular, Once, as needed for anaphylaxis. Administer to midanterior lateral thigh (vastus lateralis muscle).

If the patient does not improve, repeat dose every 5 minutes up to a maximum of 3 doses.

- ☑ cetitizine tablet 20 mg PO, Once, as needed Infusion reaction
- ☑ Acetaminophen 650 PO, Once, as needed; temp greater than 37.5 C infusion reaction
- ☑ methlyPREDNISolone sodium succinate 125 mg IV, Once, as needed infusion reaction
- ☑ NaCl 0.9%bag 500 mL, IV administer over 10 minutes, as needed hypotension
- ☑ Salbutamol 100 mcg/actuation inhaler 2 to 4 puffs, once, as needed via spacer recommended—bronchospasms. Repeat every 20 mins as required.

☐ dimenhyDRINATE 50 mg IV, Once, as needed for nausea and vomiting – infusion reaction

22214 (Rev2025-10) Page 2 of 3



# **Iron Sucrose Recurrent Treatment**

Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X)				

Emergency Medications continued							
☐ diphenhydrAMINE 50 mg IV once, as needed - infusion reaction							
☐ Hydrocortisone sodium succinate 100 mg IV, Once, as needed for treatment of pruritis, urticaria and rash only if patient is unable to take cetirizine 20 mg orally – infusion reaction							
Name MRHP	Designation						
Phone	Fax		Pager / Cell	Phone			
Signature			Date (dd-Mon	ı- <i>уууу</i> )			
Additional Patient Information							
Name of Caregiver / Guardian / Alternate	Decision Mak	ker Relationship	)	Phone			
Interpreter Required ☐ No ☐ Yes	► Specify La	inguage					
Special Considerations for Care:							

22214 (Rev2025-10) Page 3 of 3